Pfister, M

Dapagliflozin, a Novel, Selective SGLT2 Inhibitor, Improved Glycemic Control Over 2 Weeks in Patients With Type 2 Diabetes Mellitus

Komoroski, B., Vachharajani, N., Feng, Y., Li, L., Kornhauser, D., & Pfister, M. (2009) · Clinical Pharmacology & Therapeutics

Diabetes Treatment and ManagementDiabetes Management and Research

Cited by 396

Dapagliflozin, a Novel SGLT2 Inhibitor, Induces Dose-Dependent Glucosuria in Healthy Subjects

Komoroski, B., Vachharajani, N., Boulton, D., Kornhauser, D., Geraldes, M., Li, L., & Pfister, M. (2009) · Clinical Pharmacology & Therapeutics

Diabetes Treatment and ManagementDiabetes Management and Research

Cited by 350

Characterization of renal glucose reabsorption in response to dapagliflozin in healthy subjects and subjects with type 2 diabetes

DeFronzo, R. A., Hompesch, M., Kasichayanula, S., Liu, X., Hong, Y., Pfister, M., Morrow, L. A., Leslie, B. R., Boulton, D. W., Ching, A., et al. (2013) · Diabetes Care

Diabetes Treatment and ManagementDiabetes Management and Research

Cited by 293

Artificial Intelligence and Machine Learning Applied at the Point of Care

Angehrn, Z., Haldna, L., Zandvliet, A. S., Gil Berglund, E., Zeeuw, J., Amzal, B., Cheung, S. Y. A., Polasek, T. M., Pfister, M., Kerbusch, T., et al. (2020) · Frontiers in Pharmacology

Artificial Intelligence in Healthcare and EducationArtificial Intelligence in Healthcare

Cited by 93